Magnesium Sulfate in Pediatric Burn Dressing Changes

Conditions

• Pediatric Burns

Eligibility Criteria

Sex

ALL

Age

3 Years - 18 Years

Healthy Volunteers

Not accepted

Interventions

• magnesium sulfate — DRUG
  IV Magnesium Sulfate 50 mg/kg (max 2 grams) over 20 minutes given immediately prior to initiation of daily sedated dressing change
• Normal Saline (0.9% NaCl) — DRUG
  Normal Saline given in equivalent volume as study drug over 20 minutes, immediately prior to initiation of sedated dressing change

Study Details

Prospective feasibility trial utilizing adjuvant magnesium sulfate for analgesia/sedation during pediatric sedated burn dressing changes, which is ultimately hypothesized to decrease ketamine and/or sedative requirements.

Key Dates

Start date

Jan 1, 2026

Status verified

Aug 2025

Primary completion

Dec 1, 2026

Completion

Jan 1, 2027

Study Design

Enrollment

10 participants (estimated)

Allocation

RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Arms

• Experimental: Magnesium Sulfate Arm
  Pediatric Burn Patients receiving Ketamine as primary agent for sedated dressing changes, randomized (max 5 randomizations) to either study intervention (Magnesium sulfate) or placebo (Normal saline)
• Placebo Comparator: Normal Saline Placebo Arm
  Placebo

Primary Outcome Measure

Severe Adverse Events [ Time Frame: Through Study Completion, Approximately 1 year ]

Locations (1)

Find similar trials in Minneapolis, MN